PackTalk is a blog for the Healthcare Packaging Industry

160 Years of EtO


Published on January 20, 2020

Industry talk continues about a future with less or no EtO sterilization. It is a sea change, even though the controversy first appeared decades ago. It is a far cry from the buzz of a 1928 discovery that the gaseous compound was an effective insecticide. EtO quickly earned a prominent role in fumigating hospital rooms and treating WW II troop rations. These successes, no doubt, fueled the expansion of EtO use to the supply side of the medical field, sterilizing instruments.

 

As such a versatile and powerful compound, with its broad material compatibility and ability to wipe out pathogens of all sorts, EtO was the industry’s darling. Not only was it effective, but it was also adaptable and efficient for large volume sterilization in a rapidly growing field. Unfortunately, that darling had a dark side that didn’t take long to emerge.

A 1948 study found that EtO was also a mutagen, altering cells and elevating cancer risks. In the ensuing decades, further evidence against the safety of EtO grew, yet with few practical alternatives, we plodded on. Last year’s EtO sterilization crisis refocused the industry, and the FDA, on reducing the use of EtO.

As 2019 ended, the FDA rolled out a series of new actions to find new options and mitigate medical product shortfalls as we navigate our way to a safer, yet productive path:

Want more EtO history? We thought this timeline was pretty cool: https://www.chicagotribune.com/news/ct-sterigenics-eto-timeline-htmlstory.html


Comments (0)

Related Articles

One Doctor’s Request for Sustainable Change in Asia

September 17, 2021

152 kilograms. 4500 tonnes. 134 hectares. No matter how you say it, it’s not positive or sustainable. These numbers reflect the amount of medical waste from just one surgery, in a study from four hospitals over three months in New Zealand. 152 kilograms is...

Learn More

Cracking the Age Old Dilemma: Compliance or Quality?

September 17, 2021

I recently read an article from Medtech Insights on how device giants Stryker and Baxter embrace a quality first culture – and yield positive results. In the article, Stryker’s Medha Trivedi, the company’s senior director of global quality and operations said...

Learn More

Power to the PDUFA

September 17, 2021

The Prescription Drug User Fee Act was passed into law by Congress in 1992. The PDUFA implemented a fee-based framework for New Drug Applications and Biologics License Applications. One of its primary objectives was to provide funding to speed up the glacial...

Learn More

Stay Informed

To stay up to date on innovative technology and products, as well as industry trends, subscribe to Oliver’s PackTalk blog below.